🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Australia / NCT07231744
Starting soon Phase 1

Study of STLX-2012 in Healthy Volunteers

NCT07231744 · tracked via the Priya Life Science Australia tracker
Sponsor
Stelexis BioSciences
Phase
Phase 1
Started
2026-10
Last updated
2026-04-22

Condition(s) studied

Healthy Participants

Investigational drug(s) / intervention(s)

STLX-2012Placebo

STLX-2012: STLX-2012 IV

Placebo: Placebo arm

Study summary

The purpose of this research is to establish the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single IV dose of STLX-2012.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female participants aged 18-55 years old, inclusive, at Screening. * Body mass index of 18-32 kg/m\^2, inclusive * Healthy as determined by the investigator * Adequate hepatic and renal function * Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures * Male participants and females of childbearing potential must agree to use an effective method of contraception for 30 days after the last dose of STLX-2012 Exclusion Criteria: * Pregnant or lactating female. * Positive urine drug screen or alcohol breath test * Neutropenia, defined as neutrophil count \<2.0 x 10\^9/L * History of allergic reaction requiring treatment or anaphylactic reactions to any therapeutic drug. * Previous treatment with an IL-1RAP monoclonal antibody * History of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, inflammatory, or allergic disease (excluding mild seasonal allergies)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nucleus Network Brisbane Brisbane Queensland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07231744 on ClinicalTrials.gov ↗ ← All trials in Australia